Fig. 6From: RETRACTED ARTICLE: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasisHM-3 regulated EAhy926 migration in a glypican-1 dependent manner. a and b EAhy926 cells were left untreated or treated with 5 U/ml Hep I or 0.5 U/ml PI-PLC and cell migration assays were performed in the presence of 4.5 or 17.8 μM HM-3. 0.4 μM Endostatin (ES) was used as a positive control. Untreated or enzyme treated cells without peptide treatment were used as controls. The migrating cell numbers for each condition are shown in panel a and the migration inhibition rate in panel b. c-f Integrin αvβ3 and α5β1 co-localize with glypican-1. Integrin αvβ3 (c) and α5β1 (e) on cell surface are shown in green (Alexa Fluor 488) and glypican-1 in red (Alexa Fluor 647). Nuclei were counterstained with Hoechst 33342. Images were captured with an OLYMPUS workstation and analyzed with Image J software. Histograms for co-localization of integrin αvβ3 (d) or α5β1 (f) with glypican-1 as calculated by the intensities of the merged signals (*P < 0.05, **P < 0.01)Back to article page